EZH2 and cancer: The deregulation of EZH2 found in cancers includes an over-expression of wild-type protein [151,161,162] and a gain-of-function mutation resulting in a switch from tyrosine to histidine at amino acid 641(Y641H); both of which lead to a hyper-trimethylation on H3K27me3 [163].